Log in
NASDAQ:IOVA

Iovance Biotherapeutics Stock Forecast, Price & News

$37.35
+0.90 (+2.47 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$36.01
Now: $37.35▼
$37.61
50-Day Range
$28.04
MA: $35.96▼
$40.44
52-Week Range
$18.70
Now: $37.35▼
$41.60
Volume1.08 million shs
Average Volume1.70 million shs
Market Capitalization$5.48 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.94
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidates include lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma; and LN-145 for the treatment of metastatic cervical cancer. It is also developing tumor infiltrating lymphocytes (TIL) and peripheral blood lymphocyte therapies for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer, and chronic lymphocytic leukemia through its sponsored trials, as well as in other oncology indications through collaborations. Iovance Biotherapeutics, Inc. has collaboration agreements with Moffitt, M.D. Anderson Cancer Center, Ohio State University, and MedImmune; and research collaboration with Cellectis S.A. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
Read More
Iovance Biotherapeutics logo

Beat the Market (BTM) Rank™

Analyst Opinion: 4.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.86 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IOVA
Previous Symbol
CUSIPN/A
CIK1425205
Webwww.iovance.com
Phone650-260-7120
Employees148

Debt

Debt-to-Equity RatioN/A
Current Ratio14.26
Quick Ratio14.25

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.37 per share
Price / Book15.76

Profitability

EPS (Most Recent Fiscal Year)($1.59)
Net Income$-197,560,000.00
Net MarginsN/A
Return on Equity-59.35%
Return on Assets-53.22%

Miscellaneous

Outstanding Shares146,687,000
Market Cap$5.48 billion
Next Earnings Date2/23/2021 (Estimated)
OptionableOptionable
$37.35
+0.90 (+2.47 %)
(As of 11/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

How has Iovance Biotherapeutics' stock been impacted by Coronavirus?

Iovance Biotherapeutics' stock was trading at $29.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IOVA stock has increased by 26.3% and is now trading at $37.35.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Iovance Biotherapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Iovance Biotherapeutics.

What stocks does MarketBeat like better than Iovance Biotherapeutics?

Wall Street analysts have given Iovance Biotherapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Iovance Biotherapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Iovance Biotherapeutics.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) announced its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.06.
View Iovance Biotherapeutics' earnings history.

What price target have analysts set for IOVA?

11 brokers have issued twelve-month price targets for Iovance Biotherapeutics' shares. Their forecasts range from $35.00 to $65.00. On average, they anticipate Iovance Biotherapeutics' share price to reach $47.50 in the next twelve months. This suggests a possible upside of 27.2% from the stock's current price.
View analysts' price targets for Iovance Biotherapeutics.

Are investors shorting Iovance Biotherapeutics?

Iovance Biotherapeutics saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 15,160,000 shares, an increase of 17.3% from the September 30th total of 12,920,000 shares. Based on an average trading volume of 1,390,000 shares, the days-to-cover ratio is presently 10.9 days.
View Iovance Biotherapeutics' Short Interest.

Who are some of Iovance Biotherapeutics' key competitors?

Some companies that are related to Iovance Biotherapeutics include Novozymes A/S (NVZMY), argenx (ARGX), Bio-Techne (TECH), QIAGEN (QGEN), Repligen (RGEN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Novavax (NVAX), Kodiak Sciences (KOD), Halozyme Therapeutics (HALO), Twist Bioscience (TWST) and Relay Therapeutics (RLAY).
View all competitors.

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the following people:
  • Dr. Maria Fardis M.B.A., Ph.D., MBA, CEO, Pres & Director (Age 52, Pay $1.2M)
  • Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel & Corp. Sec. (Age 46, Pay $571.2k)
  • Dr. Friedrich Graf Finckenstein M.D., Chief Medical Officer (Age 53, Pay $458.51k)
  • Mr. Michael C. Swartzburg, VP of Fin. and Interim Principal Financial Officer & Principal Accounting Officer (Age 53)
  • Ms. Sara Pellegrino, VP of Investor Relations & PR
  • Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 60)
  • Dr. Elma S. Hawkins, Advisor to the Board (Age 63)

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (6.88%), BlackRock Inc. (6.24%), ARK Investment Management LLC (5.40%), Great Point Partners LLC (2.64%), Nikko Asset Management Americas Inc. (2.40%) and State Street Corp (2.16%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends for Iovance Biotherapeutics.

Which major investors are selling Iovance Biotherapeutics stock?

IOVA stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Point72 Asset Management L.P., JPMorgan Chase & Co., BlackRock Inc., Cubist Systematic Strategies LLC, State Street Corp, Victory Capital Management Inc., and Paloma Partners Management Co.
View insider buying and selling activity for Iovance Biotherapeutics.

Which major investors are buying Iovance Biotherapeutics stock?

IOVA stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Nikko Asset Management Americas Inc., PFM Health Sciences LP, Mangrove Partners, Great Point Partners LLC, Phoenix Holdings Ltd., Lord Abbett & CO. LLC, and WCM Investment Management LLC. Company insiders that have bought Iovance Biotherapeutics stock in the last two years include Iain D Dukes, Merrill A Mcpeak, and Wayne P Rothbaum.
View insider buying and selling activity for Iovance Biotherapeutics.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $37.35.

How big of a company is Iovance Biotherapeutics?

Iovance Biotherapeutics has a market capitalization of $5.48 billion. The biotechnology company earns $-197,560,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Iovance Biotherapeutics employs 148 workers across the globe.

What is Iovance Biotherapeutics' official website?

The official website for Iovance Biotherapeutics is www.iovance.com.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]

This page was last updated on 11/24/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.